TR200202030T2 - IL-18 inhibitörlerinin kullanımı. - Google Patents

IL-18 inhibitörlerinin kullanımı.

Info

Publication number
TR200202030T2
TR200202030T2 TR2002/02030T TR200202030T TR200202030T2 TR 200202030 T2 TR200202030 T2 TR 200202030T2 TR 2002/02030 T TR2002/02030 T TR 2002/02030T TR 200202030 T TR200202030 T TR 200202030T TR 200202030 T2 TR200202030 T2 TR 200202030T2
Authority
TR
Turkey
Prior art keywords
inhibitors
medicament
prevention
preparation
treatment
Prior art date
Application number
TR2002/02030T
Other languages
English (en)
Inventor
Chvatchko Yolande
Dinarello Charles
Plater-Zyberk Christine
Van Deventer Santer
Rubinstein Menachem
Novick Daniela
Kim Soo-Hyun
Original Assignee
Applied Research Systems Ars Holding N.V.
Yeda Research And Development Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V., Yeda Research And Development Company Ltd. filed Critical Applied Research Systems Ars Holding N.V.
Publication of TR200202030T2 publication Critical patent/TR200202030T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bulus, karaciger zedelenmesinin tedavi ve/veya önlenmesi için bir ilacin hazirlanmasinda IL-18'e sahip inhibitörlerin kullanimi ile ilgilidir. Bulus ayrica, artiritin, özellikle römatoid artiritin tedavi ve/veya önlenmesi için bir ilacin hazirlanmasinda IL-18 inhibitörlerinin kullanimi ile ilgilidir. Buna ilaveten bulus, enflamatuar bagirsak hastaliklarinin, özellikle Crohn hastaligi ve ülseratif kolitin tedavi ve/veya önlenmesi için bir ilacin hazirlanmasinda IL-18'e sahip inhibitörlerin kullanimi ile ilgilidir.
TR2002/02030T 2000-02-21 2001-02-20 IL-18 inhibitörlerinin kullanımı. TR200202030T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00103590 2000-02-21
EP00103597 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23

Publications (1)

Publication Number Publication Date
TR200202030T2 true TR200202030T2 (tr) 2003-01-21

Family

ID=27439934

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2002/02030T TR200202030T2 (tr) 2000-02-21 2001-02-20 IL-18 inhibitörlerinin kullanımı.
TR2005/02508T TR200502508T2 (tr) 2000-02-21 2001-02-20 IL-18 İnhibitörlerinin kullanımı.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2005/02508T TR200502508T2 (tr) 2000-02-21 2001-02-20 IL-18 İnhibitörlerinin kullanımı.

Country Status (30)

Country Link
US (1) US20030157094A1 (tr)
EP (1) EP1257292B1 (tr)
JP (1) JP4744763B2 (tr)
KR (3) KR20020086540A (tr)
CN (1) CN1322897C (tr)
AT (1) ATE506959T1 (tr)
AU (2) AU2001240636B8 (tr)
BG (1) BG66134B1 (tr)
BR (1) BR0108514A (tr)
CA (2) CA2399298C (tr)
CY (1) CY1111687T1 (tr)
CZ (1) CZ304485B6 (tr)
DE (1) DE60144514D1 (tr)
DK (1) DK1257292T3 (tr)
EA (1) EA005583B1 (tr)
EE (1) EE05423B1 (tr)
HR (1) HRP20020652A2 (tr)
HU (1) HU227752B1 (tr)
IL (2) IL151388A0 (tr)
ME (1) ME00546B (tr)
MX (1) MXPA02008079A (tr)
NO (1) NO331971B1 (tr)
NZ (3) NZ535299A (tr)
PL (1) PL206549B1 (tr)
PT (1) PT1257292E (tr)
RS (1) RS51737B (tr)
SI (1) SI1257292T1 (tr)
SK (1) SK288032B6 (tr)
TR (2) TR200202030T2 (tr)
WO (1) WO2001062285A1 (tr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
NZ535299A (en) * 2000-02-21 2006-06-30 Applied Research Systems Use of IL-18 inhibitors
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
CN100556450C (zh) * 2001-05-16 2009-11-04 耶达研究发展有限公司 Il-18抑制剂在治疗或预防脓毒症中的应用
BR0214810A (pt) * 2001-11-30 2004-11-03 Pfizer Prod Inc Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação
WO2004064713A2 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
CA2523912A1 (en) * 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
AU2004290413A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring IL-18
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP1780542A4 (en) 2004-06-30 2008-05-14 Atsuo Sekiyama AGENT INDICATING A NON-INFLAMMATORY RESPONSE TO A STRESS AND USE THEREOF
EP1808446B1 (en) * 2004-07-16 2012-01-18 Atsuo Sekiyama Il-18 receptor antagonist and pharmaceutical composition containing the antagonist
ES2385639T3 (es) 2005-06-03 2012-07-27 Ares Trading S.A. Producción de una proteína de unión a IL-18 recombinante
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
AU2007267213B2 (en) 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
PT3041864T (pt) * 2013-09-05 2021-10-26 Ab2 Bio Sa Proteína de ligação a il-18 (il-18bp) em doenças inflamatórias
UA128752C2 (uk) 2015-03-05 2024-10-16 Аб2 Біо Са Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
US20210115131A1 (en) * 2018-06-14 2021-04-22 Université De Bordeaux Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
EP4371573A4 (en) 2021-07-13 2025-08-20 National Univ Corporation Tokai National Higher Education And Research System MEDICINAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒
WO2025229563A1 (en) * 2024-05-03 2025-11-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating inflammatory bowel disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
PT936923E (pt) * 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
NZ535299A (en) * 2000-02-21 2006-06-30 Applied Research Systems Use of IL-18 inhibitors
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CZ304485B6 (cs) 2014-05-28
DK1257292T3 (da) 2011-07-18
SK288032B6 (sk) 2012-12-03
PT1257292E (pt) 2011-07-05
PL206549B1 (pl) 2010-08-31
WO2001062285A1 (en) 2001-08-30
EE200200463A (et) 2003-12-15
EE05423B1 (et) 2011-06-15
CN1404400A (zh) 2003-03-19
CY1111687T1 (el) 2015-10-07
CA2683009A1 (en) 2001-08-30
HUP0300061A3 (en) 2005-09-28
ME00546B (me) 2011-10-10
RS51737B (sr) 2011-10-31
CA2683009C (en) 2014-09-23
BG66134B1 (bg) 2011-06-30
KR20020086540A (ko) 2002-11-18
HUP0300061A2 (hu) 2003-04-28
AU2001240636B2 (en) 2005-10-13
HK1051965A1 (en) 2003-08-29
EP1257292B1 (en) 2011-04-27
YU60402A (sh) 2005-09-19
AU4063601A (en) 2001-09-03
NO20023962L (no) 2002-08-20
SK12082002A3 (sk) 2003-05-02
AU2001240636B8 (en) 2005-11-03
JP4744763B2 (ja) 2011-08-10
ATE506959T1 (de) 2011-05-15
BR0108514A (pt) 2002-12-17
IL151388A0 (en) 2003-04-10
KR20070087256A (ko) 2007-08-27
NO20023962D0 (no) 2002-08-20
EA200200890A1 (ru) 2003-02-27
CA2399298A1 (en) 2001-08-30
EP1257292A1 (en) 2002-11-20
HU227752B1 (en) 2012-02-28
SI1257292T1 (sl) 2011-08-31
HRP20020652A2 (en) 2004-12-31
CN1322897C (zh) 2007-06-27
NZ535299A (en) 2006-06-30
CZ20022843A3 (cs) 2003-02-12
JP2003523403A (ja) 2003-08-05
BG107018A (bg) 2003-09-30
CA2399298C (en) 2014-04-15
KR20070057282A (ko) 2007-06-04
NO331971B1 (no) 2012-05-14
MXPA02008079A (es) 2003-02-27
TR200502508T2 (tr) 2007-04-24
DE60144514D1 (de) 2011-06-09
NZ546294A (en) 2008-02-29
EA005583B1 (ru) 2005-04-28
IL151388A (en) 2009-09-01
US20030157094A1 (en) 2003-08-21
PL357554A1 (en) 2004-07-26
NZ520122A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
DE60144514D1 (de) Verwendung von il-18 inhibitoren
NO20034312L (no) Terapeutiske midler mot inflammatoriske tarmsykdommer
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
EE200100618A (et) Dieet- või farmatseutiline kompositsioon kasutamiseks hüperoksaluuria vältimiseks või raviks
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
DE60133887D1 (de) Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber
WO2006034001A3 (en) Methods of treating hiv infection
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
EP1604671A4 (en) MUSCLE TREATMENT AND MEANS FOR PREVENTING OR TREATING MUSCLE WEAKNESS
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
EP1116488A3 (en) Treatment of inflammatory Bowel disease
PT1049480E (pt) Agente herbaceo antiviral
MX2009004196A (es) Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de enfermedades autoinmunes.
HUP0300083A3 (en) Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
ITMI20021005A0 (it) Composizioni farmaceutiche ad attivita' antitumorale in particolare per il trattamento di leucemie e glioblastomi
WO2004037971A3 (en) Use of heterocyclic amine-type compounds as neuroprotective agents
MD2066G2 (ro) Remediu antihipertensiv
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
IT1311913B1 (it) Impiego di 6-metilmercaptopurina riboside in composizionioftalmologiche.
TH90961B (th) การรักษาเชิงบำบัด
MD1919F2 (en) Medicinal remedy